GlassScriptPhysician profile
Sean Feng
NPI 1417427535
$1,958.64
in general payments reported to CMS, 2019-2025
35 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.10 · 2022: $272 · 2023: $628 · 2024: $597 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.10 |
| Education | $245.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $230.93 | 2023-2024 | Jakafi |
| Abbvie INC. | $228.93 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.99 | 2022-2023 | |
| Glaxosmithkline, LLC. | $122.41 | 2022-2025 | Ojjaara, Blenrep |
| Mirati Therapeutics, INC. | $118.95 | 2023 | Krazati |
| Epizyme, INC. | $99.00 | 2022 | |
| Amgen INC. | $83.39 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $71.77 | 2023-2025 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $67.24 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Astrazeneca Pharmaceuticals LP | $66.82 | 2025 | Lynparza, Wainua |
| Seagen INC. | $52.43 | 2021-2023 | Adcetris |
| Merck Sharp & Dohme LLC | $49.58 | 2023-2024 | Keytruda, Lynparza |
| Genentech USA, INC. | $47.51 | 2024-2025 | Polivy, Ocrevus Zunovo |
| Puma Biotechnology, INC. | $36.68 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $35.56 | 2025 | Givlaari |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $30.93 | 2025 | Gomekli |
| Janssen Biotech, INC. | $28.76 | 2024 | Tremfya |
| Pfizer INC. | $27.63 | 2024 | |
| Daiichi Sankyo INC. | $25.48 | 2024 | Injectafer |
| Jazz Pharmaceuticals INC. | $25.27 | 2024 | |
| Cti Biopharma Corp. | $24.96 | 2023 | Vonjo |
| Array Biopharma INC | $24.52 | 2023 | Mektovi, Lorbrena, Braftovi |
| Beone Medicines USA, INC. | $23.05 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $23.05 | 2024 | |
| Foundation Medicine, INC. | $22.99 | 2023 | |
| Exelixis INC. | $22.45 | 2023 | Cabometyx |
| Celgene Corporation | $22.43 | 2023 | Reblozyl |
| Genmab U.S., INC. | $21.40 | 2025 | Tivdak |
| Novocure INC. | $20.38 | 2025 | Optune Gio |
| Kyowa Kirin, INC. | $19.93 | 2023 | Poteligeo |
| Lilly USA, LLC | $19.86 | 2023 | Verzenio, Retevmo, Jaypirca |
| Novartis Pharmaceuticals Corporation | $18.12 | 2025 | |
| Eisai INC. | $17.07 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.46 | 2024 | |
| Legend Biotech USA INC. | $14.71 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Feng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.